Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.06 is 74% below its 2-year average of 0.23, near the low end of its 2-year range (0.00–1.56).
As of the fiscal period ended Tuesday, June 30, 2026. 82.94% below its 12-month average of 0.34.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.06.
DEBT TO EQUITY RATIO
0.06
DEBT TO EQUITY RATIO AVG TTM
0.34
DEBT TO EQUITY RATIO AVG 3Y
N/A
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-82.94%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 711 covered companies
CURRENT VS SECTOR MEDIAN
-47.52%
vs the sector median at left
Curanex Pharmaceuticals Inc Common Stock
Market Cap
$6.90M
Debt to Equity Ratio
0.06
TTM Avg
0.34
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$6.82M
Debt to Equity Ratio
0.14
TTM Avg
0.05
3Y Avg
0.03
5Y Avg
0.02
Market Cap
$6.99M
Debt to Equity Ratio
1.71
TTM Avg
0.66
3Y Avg
0.41
5Y Avg
0.34
Market Cap
$7.00M
Debt to Equity Ratio
0.03
TTM Avg
0.02
3Y Avg
0.20
5Y Avg
0.20
Market Cap
$6.98M
Debt to Equity Ratio
N/A
TTM Avg
0.03
3Y Avg
0.02
5Y Avg
0.01
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Curanex Pharmaceuticals Inc Common Stock (CURX) | $6.90M | 0.06 | 0.34 | N/A | N/A |
| Exicure, Inc. (XCUR)vs › | $6.82M | 0.00 | 0.46 | 0.90 | 0.89 |
| Co-Diagnostics, Inc. (CODX)vs › | $6.82M | 0.14 | 0.05 | 0.03 | 0.02 |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.99M | 1.71 | 0.66 | 0.41 | 0.34 |
| Mangoceuticals, Inc. (MGRX)vs › | $7.00M | 0.03 | 0.02 | 0.20 | 0.20 |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $6.98M | N/A | 0.03 | 0.02 | 0.01 |
| KALA BIO, Inc. (KALA)vs › | $7.08M | 0.00 | 1.31 | 2.43 | 2.58 |
| Aclarion, Inc. (ACON)vs › | $6.66M | 0.00 | 0.00 | 0.00 | 0.00 |
| Biomerica, Inc. (BMRA)vs › | $6.54M | 0.72 | 0.51 | 0.31 | 0.26 |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.53M | 0.00 | 0.00 | 0.00 | 0.00 |
Debt/Equity
0.06
Current Ratio
45.95
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.06 |
| 2026-03-31 | 0.04 |
| 2025-12-31 | 0.03 |
| 2025-09-30 | 0.00 |
| 2025-06-30 | 1.56 |
| 2025-03-31 | 0.80 |
| 2024-12-31 | 0.00 |
| 2024-09-30 | 0.00 |
| 2024-06-30 | 0.00 |
| 2024-03-31 | 0.00 |
| 2023-12-31 | 0.00 |
